Back to Search Start Over

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.

Authors :
Rosas, Juan C.
Aguado‐Barrera, Miguel E.
Azria, David
Briers, Erik
Elliott, Rebecca
Farcy‐Jacquet, Marie‐Pierre
Giraldo, Alexandra
Gutiérrez‐Enríquez, Sara
Rancati, Tiziana
Rattay, Tim
Reyes, Victoria
Rosenstein, Barry
De Ruysscher, Dirk
Sperk, Elena
Stobart, Hilary
Talbot, Christopher
Vega, Ana
Taboada‐Valladares, Begoña
Veldeman, Liv
Ward, Tim
Source :
International Journal of Cancer; Nov2023, Vol. 153 Issue 9, p1579-1591, 13p
Publication Year :
2023

Abstract

Fatigue is common in breast‐cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long‐term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI‐20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post‐RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI‐20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P <.05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI‐20 fatigue dimensions (ORGeneralFatigue = 3.81, P <.001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00207136
Volume :
153
Issue :
9
Database :
Complementary Index
Journal :
International Journal of Cancer
Publication Type :
Academic Journal
Accession number :
171583196
Full Text :
https://doi.org/10.1002/ijc.34640